DiaMedica Therapeutics (DMAC) Short Interest Ratio & Short Volume → Alert: Your Bank is Dying – Act Now or Lose Everything! (From Priority Gold) (Ad) Free DMAC Stock Alerts $2.82 -0.13 (-4.41%) (As of 06/4/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DiaMedica Therapeutics Short Interest DataCurrent Short Interest128,600 sharesPrevious Short Interest182,000 sharesChange Vs. Previous Month-29.34%Dollar Volume Sold Short$387,086.00Short Interest Ratio3.3 Days to CoverLast Record DateMay 15, 2024Outstanding Shares37,960,000 sharesPercentage of Shares Shorted0.34%Today's Trading Volume23,787 sharesAverage Trading Volume28,615 sharesToday's Volume Vs. Average83% Short Selling DiaMedica Therapeutics ? Sign up to receive the latest short interest report for DiaMedica Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDMAC Short Interest Over TimeDMAC Days to Cover Over TimeDMAC Percentage of Float Shorted Over Time Ad Colonial MetalsCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.In answer to this issue, we have released a Special Report to the public. DiaMedica Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/2024128,600 shares $387,086.00 -29.3%N/A3.3 $3.01 4/30/2024182,000 shares $469,560.00 +3.8%N/A4.3 $2.58 4/15/2024175,400 shares $419,206.00 -13.3%N/A4.4 $2.39 3/31/2024202,200 shares $560,094.00 -4.9%N/A4.8 $2.77 3/15/2024212,600 shares $644,178.00 +8.3%N/A5 $3.03 2/29/2024196,300 shares $588,900.00 +3.7%N/A4.7 $3.00 Get the Latest News and Ratings for DMAC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024189,300 shares $567,900.00 -3.3%N/A4.4 $3.00 1/31/2024195,700 shares $551,874.00 -3.1%N/A4 $2.82 1/15/2024202,000 shares $603,980.00 +7.0%N/A4 $2.99 12/31/2023188,800 shares $536,192.00 -2.2%N/A3.8 $2.84 12/15/2023193,100 shares $531,025.00 +5.4%N/A3.7 $2.75 11/30/2023183,300 shares $447,252.00 -24.9%N/A3.1 $2.44 11/15/2023244,200 shares $598,290.00 0.0%N/A4 $2.45 10/31/2023244,300 shares $532,574.00 +11.5%N/A4 $2.18 10/15/2023219,100 shares $449,155.00 -1.1%N/A2.9 $2.05 9/30/2023221,500 shares $571,470.00 +0.7%N/A2.3 $2.58 9/15/2023219,900 shares $712,476.00 -0.8%N/A1.8 $3.24 8/31/2023221,700 shares $654,015.00 -9.4%N/A1.5 $2.95 8/15/2023244,600 shares $725,239.00 -10.6%N/A1.5 $2.97 7/31/2023273,500 shares $924,430.00 -65.7%N/A1.6 $3.38 7/15/2023796,100 shares $3.01 million +11.6%4.5%5.4 $3.78 6/30/2023713,600 shares $3.08 million +910.8%4.0%5.4 $4.32 6/15/202370,600 shares $224,508.00 +7.1%0.4%0.7 $3.18 5/31/202365,900 shares $179,907.00 -21.2%0.4%1.1 $2.73 5/15/202383,600 shares $166,196.80 -9.0%0.5%1.9 $1.99 4/30/202391,900 shares $149,797.00 -5.7%0.5%3.4 $1.63 4/15/202397,400 shares $155,840.00 +6.5%0.6%3.4 $1.60 3/31/202391,500 shares $139,995.00 +55.6%0.5%2.9 $1.53 3/15/202358,800 shares $104,664.00 +44.8%0.4%1.5 $1.78 2/28/202340,600 shares $70,238.00 -1.7%0.3%0.7 $1.73 2/15/202341,300 shares $62,363.00 +22.6%0.3%0.7 $1.51 1/31/202333,700 shares $45,495.00 -57.8%0.2%0.5 $1.35 1/15/202379,800 shares $130,872.00 -6.5%0.5%1.2 $1.64 12/30/202285,300 shares $134,782.53 +113.8%0.5%1.3 $1.58 12/15/202239,900 shares $60,249.00 -7.0%0.2%0.6 $1.51 11/30/202242,900 shares $51,051.00 +24.4%0.2%0.7 $1.19 11/15/202234,500 shares $39,330.00 -35.0%0.2%0.6 $1.14 10/31/202253,100 shares $62,658.00 -47.5%0.3%0.9 $1.18 10/15/2022101,200 shares $153,824.00 +245.4%0.6%1.9 $1.52 9/30/202229,300 shares $36,332.00 -61.7%0.2%0.4 $1.24The Petrodollar Scheme Comes to an End (Ad)The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.In answer to this issue, we have released a Special Report to the public. 9/15/202276,500 shares $110,925.00 +153.3%0.4%0.5 $1.45 8/31/202230,200 shares $53,454.00 -43.6%0.2%0.2 $1.77 8/15/202253,500 shares $96,835.00 -0.2%0.3%0.4 $1.81 7/31/202253,600 shares $88,440.00 +10.7%0.3%0.4 $1.65 7/15/202248,400 shares $61,952.00 -8.2%0.3%0.4 $1.28 6/30/202252,700 shares $106,454.00 +5.0%0.3%0.4 $2.02 6/15/202250,200 shares $110,440.00 -1.6%0.3%1.1 $2.20 5/31/202251,000 shares $123,930.00 -50.3%N/A1.2 $2.43 5/15/2022102,700 shares $250,588.00 +85.4%N/A2.3 $2.44 4/30/202255,400 shares $128,528.00 +62.5%N/A1.2 $2.32 4/15/202234,100 shares $79,112.00 +5.9%N/A0.6 $2.32 3/31/202232,200 shares $80,500.00 -45.8%N/A0.5 $2.50 3/15/202259,400 shares $136,620.00 -26.0%N/A0.7 $2.30 2/28/202280,300 shares $211,189.00 -23.5%N/A0.7 $2.63 2/15/2022104,900 shares $325,190.00 +21.6%N/A0.9 $3.10 1/31/202286,300 shares $223,517.00 +14.9%0.5%0.6 $2.59 1/15/202275,100 shares $253,838.00 +22.1%0.4%0.4 $3.38 12/31/202161,500 shares $229,395.00 -22.5%0.3%0.4 $3.73 12/15/202179,300 shares $307,684.00 +55.8%0.4%0.4 $3.88 11/30/202150,900 shares $190,366.00 -26.9%0.3%0.3 $3.74 11/15/202169,600 shares $280,488.00 -21.5%0.4%0.3 $4.03 10/29/202188,700 shares $350,365.00 -7.9%0.6%0.4 $3.95 10/15/202196,300 shares $394,830.00 +62.4%0.6%0.5 $4.10 9/30/202159,300 shares $237,793.00 +9.6%N/A0.3 $4.01 9/15/202154,100 shares $209,367.00 +29.7%0.3%0.2 $3.87 8/31/202141,700 shares $179,310.00 +85.3%0.2%0.1 $4.30 8/13/202122,500 shares $69,750.00 -59.4%0.1%0.1 $3.10 7/30/202155,400 shares $191,130.00 -23.9%0.3%0.2 $3.45 7/15/202172,800 shares $264,992.00 -47.5%0.4%0.3 $3.64 6/30/2021138,700 shares $617,215.00 -26.9%0.8%0.6 $4.45 6/15/2021189,800 shares $1.64 million +27.7%1.1%1.9 $8.63 5/28/2021148,600 shares $1.10 million -6.8%0.9%1.6 $7.41 5/14/2021159,400 shares $1.03 million -2.8%N/A1.5 $6.47 4/30/2021164,000 shares $1.56 million -12.3%N/A1.4 $9.50 4/15/2021187,000 shares $1.78 million +8.4%N/A1.5 $9.54 3/31/2021172,500 shares $1.58 million +10.0%N/A1.2 $9.18 3/15/2021156,800 shares $1.53 million +34.5%N/A0.8 $9.74 2/26/2021116,600 shares $1.08 million +40.5%N/A0.6 $9.25 2/12/202183,000 shares $728,740.00 -10.9%N/A0.3 $8.78 1/29/202193,100 shares $722,456.00 +17.0%N/A0.4 $7.76 1/15/202179,600 shares $780,876.00 -19.7%N/A0.4 $9.81 12/31/202099,100 shares $969,198.00 +145.9%N/A0.5 $9.78 12/15/202040,300 shares $257,517.00 +75.2%N/A0.2 $6.39 11/30/202023,000 shares $132,250.00 +10.1%N/A0.2 $5.75 11/15/202020,900 shares $87,362.00 -34.7%N/A0.3 $4.18 10/30/202032,000 shares $132,160.00 +33.3%N/A0.7 $4.13 10/15/202024,000 shares $114,000.00 +8.1%N/A0.4 $4.75 9/30/202022,200 shares $94,128.00 +7.8%N/A0.4 $4.24 9/15/202020,600 shares $88,786.00 -21.1%N/A0.4 $4.31 8/31/202026,100 shares $123,975.00 +12.5%N/A0.4 $4.75The Petrodollar Scheme Comes to an End (Ad)The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.In answer to this issue, we have released a Special Report to the public. 8/14/202023,200 shares $124,120.00 +373.5%N/A0.3 $5.35 7/31/20204,900 shares $29,155.00 -54.2%N/A0.1 $5.95 7/15/202010,700 shares $63,130.00 -15.8%N/A0.1 $5.90 6/30/202012,700 shares $85,344.00 -35.2%N/A0.2 $6.72 6/15/202019,600 shares $91,728.00 -14.0%0.2%0.3 $4.68 5/29/202022,800 shares $105,336.00 -33.9%0.2%0.4 $4.62 5/15/202034,500 shares $155,250.00 +155.6%0.3%0.6 $4.50 4/30/202013,500 shares $54,675.00 +82.4%0.1%0.3 $4.05 4/15/20207,400 shares $23,236.00 +124.2%0.1%0.2 $3.14 3/31/20203,300 shares $12,045.00 -10.8%0.0%0.1 $3.65 3/13/20203,700 shares $10,952.00 -30.2%0.0%0.1 $2.96 2/28/20205,300 shares $12,243.00 -51.4%0.1%0.1 $2.31 2/14/202010,900 shares $44,581.00 +29.8%0.1%0.2 $4.09 1/31/20208,400 shares $42,504.00 -46.5%0.1%0.2 $5.06 1/15/202015,700 shares $69,237.00 -56.6%0.2%0.4 $4.41 12/31/201936,200 shares $151,678.00 +46.6%0.4%0.8 $4.19 DMAC Short Interest - Frequently Asked Questions What is DiaMedica Therapeutics' current short interest? Short interest is the volume of DiaMedica Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 128,600 shares of DMAC short. Learn More on DiaMedica Therapeutics' current short interest. What is a good short interest ratio for DiaMedica Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DMAC shares currently have a short interest ratio of 3.0. Learn More on DiaMedica Therapeutics's short interest ratio. Which institutional investors are shorting DiaMedica Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of DiaMedica Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is DiaMedica Therapeutics' short interest increasing or decreasing? DiaMedica Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 128,600 shares, a decrease of 29.3% from the previous total of 182,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does DiaMedica Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to DiaMedica Therapeutics: Mural Oncology plc (8.50%), LianBio (0.36%), Enlivex Therapeutics Ltd. (1.10%), PolyPid Ltd. (0.53%), PHAXIAM Therapeutics S.A. (0.01%), Tenax Therapeutics, Inc. (0.52%), Processa Pharmaceuticals, Inc. (1.90%), NeuBase Therapeutics, Inc. (0.51%), Biogen Inc. (2.41%), and Pfizer Inc. (1.24%). Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short DiaMedica Therapeutics stock? Short selling DMAC is an investing strategy that aims to generate trading profit from DiaMedica Therapeutics as its price is falling. DMAC shares are trading down $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against DiaMedica Therapeutics? A short squeeze for DiaMedica Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DMAC, which in turn drives the price of the stock up even further. How often is DiaMedica Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DMAC, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Mural Oncology Short Interest LianBio Short Interest Enlivex Therapeutics Short Interest PolyPid Short Interest PHAXIAM Therapeutics Short Interest Tenax Therapeutics Short Interest Processa Pharmaceuticals Short Interest NeuBase Therapeutics Short Interest 180 Life Sciences Short Interest Alpha Tau Medical Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DMAC) was last updated on 6/5/2024 by MarketBeat.com Staff From Our PartnersThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…Porter & Company| SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes| SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold| SponsoredTrump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absoluteDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold| SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredEverything from semiconductors to space shuttles depend on this overlooked mineralBoron is also at the heart of a breakthrough that could fuel one of mankind's most sensational advances in sem...Capital Trends| SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals| SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.